alexa Treatment of Hypertension in Patients with Coronary Artery Disease
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Treatment of Hypertension in Patients with Coronary Artery Disease

Abdul Rashid Abdul Rahman1* and Raudah Mohd Yunus2

1Consultant Cardiovascular Physician and Visiting Professor, An Nur Specialist Hospital, Bandar Baru Bangi, Selangor, Malaysia

2Department of Population Health and Preventive Medicine, Faculty of Medicine, University of Technology, Malaysia

*Corresponding Author:
Abdul Rashid Abdul Rahman
Consultant Cardiovascular Physician and Visiting Professor, An Nur Specialist Hospital, Internal Medicine
Lot 14 &16, Medan Pusat Bandar 1, Section 9, Bandar Baru Bangi
Kajang, Selangor 43000, Malaysia
Tel: +6012 9892399
E-mail: [email protected]

Received date: October 31, 2016; Accepted date: December 07, 2016; Published date: December 10, 2016

Citation: Rahman ARA, Yunus RM (2016) Treatment of Hypertension in Patients with Coronary Artery Disease. J Clin Exp Cardiolog 7:484. doi: 10.4172/2155-9880.1000484

Copyright: © 2016 Rahman ARA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Hypertension is among the leading causes of mortality worldwide, both in the developed and developing world. Most deaths occur due to cardiovascular complications such as myocardial infarction (MI) and stroke. In the Asia Pacific Region, hypertension alone contributes to 66% of all cardiovascular deaths, more than it does worldwide.

The most recent meta-analysis on the benefits of treating hypertension showed that tighter control of blood pressure (133/76 mmHg) leads to a significant 14% reduction in myocardial infraction. In patients with concurrent Coronary Artery Disease (CAD) the two issues which need to be addressed are: 1) to determine the target of blood pressure (BP), and; 2) to determine the drug of choice in hypertensive patients with concurrent CAD.

Up to five years ago, most Clinical Practice Guidelines suggested that target BP to be achieved was <130/80 mmHg. This however was revised recently to <140/90 mmHg. The new cut-off was mainly due to lack of evidence from randomized controlled trials on the lower BP of <130/80 mmHg and the persistence concern about the J curve.

This article reviewed recommendations made by the latest Hypertension Guidelines across major hypertension societies in North America, Europe and the Asia Pacific Region published over the last 3 years in the English language. These were than compared with major clinical outcome studies investigating phenotype of patients with hypertension and CAD. The treatment of choice for patients with CAD depends on clinical circumstances. In patients with underlying CAD, calcium channel blockers (verapamil) and beta blockers (atenolol) are indicated based on the INVEST trial. Besides, ACE I should also be the treatment of choice as indicated by the EUROPA trial especially in patients with minimal symptomatic angina. Beta blockers and dihydropyridine calcium channel blockers are indicated for symptomatic angina although there is no evidence of their impact on prognosis. For patients with previous myocardial infarction and normal left ventricular ejection fraction , ACE I and beta blockers are the drugs of choice to improve prognosis and clinical outcome although doubt has been raised on the benefits of beta blockers especially for mortality reduction. As for post-MI patients with reduced left ventricular ejection fraction, ACE I (or ARB), beta blockers and aldosterone antagonist are indicated.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords